V-Bio Ventures portfolio company Dualyx raises €40 million to progress Treg therapies for autoimmune diseases into the clinic Use of proceeds will enable the development of the Company’s lead autoimmune program DT-001, targeting TNFR2, as well as its […] May 15, 2023 · V-Bio Ventures
Talking T cells with David Masopust Immunology is a complex but vitally important branch of the life sciences. Earlier this year, we attended a Keystone Symposia […] June 8, 2020 · BioVox
Fundamental research leads to treatment breakthrough in rare genetic diseases A basic research breakthrough is improving patient lives, as researchers realized their rare genetic condition could be treated by repurposing […] June 8, 2020 · BioVox
To prevent another pandemic, we need to improve our relationship with animals The new coronavirus did not come as a bolt from the blue. For many years, the World Health Organization (WHO) […] June 8, 2020 · BioVox
Newton Biocapital I invests in J-Pharma Co., Ltd. in Japan focusing on drug development targeting L-type Amino Acid Transporter 1 (LAT1) for cancer and autoimmune diseases Brussels, Belgium / Tokyo, Japan – 27 August 2020 – Newton Biocapital I (“Newton”), an investment company in life sciences, […] August 27, 2020 · Quality by Design - Business & Communications
Biodol Therapeutics receives EUR 4.5 million to progress its novel pain medication in a Series A led by V-Bio Ventures V-Bio Ventures, a leading Belgian life sciences VC, invests in Biodol Therapeutics, a French biotech specialized in next-generation chronic pain […] August 31, 2020 · V-Bio Ventures
A novel approach to neurology could bring relief to people in pain In August 2020, V-Bio Ventures announced their investment in Biodol Therapeutics, a French start-up looking to make a difference to […] August 31, 2020 · V-Bio Ventures
Countering COVID-19 with llama antibodies In July 2020, VIB spin-off ExeVir Bio raised €23 million to advance a llama-derived antibody against COVID-19. The company is […] August 31, 2020 · BioVox
Montis Biosciences appoints Karen Zinkewich-Péotti as Chief Executive Officer Leuven, Belgium, 29 September 2020 – Montis Biosciences, a discovery stage biotech company focused on novel immuno-oncology therapeutics targeting the […] September 29, 2020 · Quality by Design - Business & Communications
Vascular dysfunction meets immune suppression Tumors create complex microenvironments where they suppress the normal functioning of the immune system. Blood vessels and macrophages are an […] November 4, 2020 · BioVox
Newton Biocapital I invests in Perseus Proteomics Inc. in Japan to develop therapeutic antibodies for the treatment of blood cancers Brussels, Belgium / Tokyo, Japan – 1 December 2020 – Newton Biocapital I (“Newton”), a life sciences investment fund active in Europe […] December 1, 2020 · Quality by Design - Business & Communications
Decades-old discoveries cause paradigm shifts in modern medicine Complete paradigm shifts in medicine are rare, but there have nevertheless been several major examples in the past hundred years. […] December 16, 2020 · V-Bio Ventures
One year of COVID-19: a look back at 2020 and where we are now One year on from the emergence of SARS-COV-2 in Wuhan, China, this novel coronavirus continues to devastate the world. Since […] January 27, 2021 · BioVox
Onco-immunology Company Pan Cancer T Launched as Spin-off from Erasmus Medical Center – Dutch biotech company developing first-in-class T-cell Receptor (TCR) T-cell therapies – Seed investment by Swanbridge Capital and Van Herk […] February 8, 2021 · Quality by Design - Business & Communications
Record-breaking pollen levels linked to increased risk of COVID-19 Increased pollen concentrations are correlated with higher rates of COVID-19. Hot on the heels of record-breaking European pollen counts, this […] March 10, 2021 · BioVox